2025 Q3 -tulosraportti
8 päivää sittenTarjoustasot
Nasdaq Stockholm
Määrä
Osto
62
Myynti
Määrä
50 439
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 41 | - | - | ||
| 3 | - | - | ||
| 6 | - | - | ||
| 12 | - | - | ||
| 250 | - | - |
Ylin
0,3VWAP
Alin
0,283VaihtoMäärä
1 3 456 106
VWAP
Ylin
0,3Alin
0,283VaihtoMäärä
1 3 456 106
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 24.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 26.11. | |
| 2025 Q2 -tulosraportti | 28.8. | |
| 2025 Q1 -tulosraportti | 14.5. | |
| 2024 Q4 -tulosraportti | 25.2. | |
| 2024 Q3 -tulosraportti | 27.11.2024 |
Datan lähde: Quartr, FactSet
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·9 t sittenThere isn't much news to be found at the moment. I asked Gemini AI a bit about these clinics and KOLs. Got this as an explanation for the news drought: 1. Targeted Advocacy Strategy (Focus on Quality over Quantity) Immunovia is currently in the "Targeted Advocacy" phase of their commercial launch. Initial Goal: The primary objective is not to maximize the number of centers, but to establish the test within the most influential, Key Opinion Leader (KOL)-led High-Risk Surveillance Centers (HRSCs). The Power of the First 10: Announcing the first set of 7 (and then the quick expansion to 10) was a key milestone to demonstrate proof of concept and KOL validation. Once that message is delivered, simply adding centers 11, 12, and 13 becomes less impactful public relations. Quiet Trust-Building: The commercial strategy is to work closely and quietly with these initial centers to build test volume and gather clinical utility data. These small, steady wins are vital for the business but not material enough for individual press releases. 2. Avoiding Unnecessary Revenue Expectations Announcing every new center can set an unrealistic expectation for revenue growth among investors. Since PancreaSure is currently a patient-pay test (until full Medicare/insurance reimbursement kicks in, which is planned for 2026), the initial test volume is expected to be modest. Each new center might only order a handful of tests initially as they integrate it into their protocol. Drip-feed announcements of small clinical wins could lead to investor fatigue or panic if the revenue numbers don't immediately follow the center count. Immunovia is likely waiting to announce a consolidated milestone (e.g., "We have secured 25 HRSCs," or "Quarterly test volume has doubled"). 3. Focus on Major Financial Milestones For a publicly traded company, press releases are generally reserved for material, market-moving events (those that could reasonably affect the share price). The company is prioritizing major milestones that unlock substantial future revenue: Final Medicare Payment Rate ($897): This was announced because it directly addresses the reimbursement bottleneck. Rights Issue/Financing: Announced to ensure liquidity. Major Validation Studies (CLARITI/VERIFI): Announced to provide scientific credibility. Adding center 11 is important for the sales team, but securing the Medicare price is what opens the door to the target 1.8 million high-risk U.S. individuals—a far more impactful announcement. In short, the lack of a press briefing for every new center is a sign of a focused, disciplined commercial strategy that prioritizes deep, high-quality adoption by key medical centers over a public relations race to count the most locations.
·8 t sitten · MuokattuWe'll see if more centers emerge in December. Their goal was to collaborate with 15-20 by the end of 2025, and as it looks now, they don't seem to be able to meet that goal, unless they are very fast. I think it's very quiet. Their previous test, IMMray, was available at 23 centers.·7 t sittenDon't forget the Christmas rally before and after New Year
·14 t sitten · Muokattu* Pancreasure is the only reliable blood test for early pancreatic cancer. * Price $897, set by Medicare/Medicaid * Today it is offered for $750 at approximately 20 selected clinics and patients, if they are financially vulnerable, can get the price significantly reduced. * A blood test takes a few minutes to perform by a nurse. The best alternative, which has much higher accuracy, is EUS-FNB (endoscopic ultrasound-assisted fine-needle biopsy), i.e., one goes in with a needle probe through the esophagus into the stomach and perforates the bottom, inserts the needle into the pancreas which is located in the middle of the abdominal cavity under the stomach. All the time guided by ultrasound. It therefore requires a full medical team including an anesthesiologist. It takes a lot of time and several doctor's visits. It costs a total of $5000-$15000 when one includes * Pre-op imaging diagnostics * Pre-op lab Anesthesia * Facility fee * Pathology * Consultations With insurance, the patient pays $500-$4500 Here are some quotes: Dr. Diane Simeone, Director of Moores Cancer Center at UC San Diego and Founding Director of the PRECEDE Consortium, added that, “The PRECEDE Consortium is pleased to be collaborating with Immunovia as part of our common goal of finding a way to reliably detect pancreatic cancer at its earliest, most treatable stages.” Professor Bryson Katona, MD, Director, Gastrointestinal Cancer Genetics Program, University of Pennsylvania Perelman School of Medicine: ”The launch of the PancreaSure test is an important advance in pancreatic cancer surveillance. We have long recognized the need for blood-based tests to accurately detect early-stage pancreatic cancer in high-risk individuals and we are excited to offer this test in our program.” Bryson Katona also presented PancreaSure during the conference The Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC) on October 10 - in his capacity as former chairman and also a member of Immunovia's Scientific Advisory Board. Erkut Borazanci, MD, Medical Director, HonorHealth Research Institute, Oncology Research Division ”People at risk for pancreatic cancer often ask if there is a blood test to detect the disease. PancreaSure is a big step in that direction. It’s exciting to be able to offer high-risk individuals a convenient blood test that can be used in conjunction with imaging that may be able to detect pancreatic cancer.” Rosario Ligesti, MD, Chief of Gastroenterology, Hackensack Medical Center ”Pancreatic cancer is so lethal because it’s usually diagnosed too late. We need more ways to detect pancreatic cancer early, especially in people at high risk. The PancreaSure test has proven to accurately detect stage 1 and 2 disease, making it an important addition to our toolkit.”·13 t sitten · MuokattuThanks for trying to provide good data. I think we should be glad that Jeff Borcherdinger is not the type of CEO who churns out reports indiscriminately. I have observed other public limited companies that are a bit less serious. I think he has done as well as he can with the data he has had. We naturally had to go through the share issue. It turned out as it did with a stream of perfectly fine news that hit at not entirely optimal times. It was serious. Otherwise, one notices that the low volume is unfortunately being used by short traders again. Also, there is just as much downward manipulation for the share price as there is upward manipulative type. Down possibly wins because there are short opportunities. It is quite clear that the one with the deepest pockets is using the current opportunity to wear out owners into selling. That's their game when they can gradually build up a few more and more shares. Well aided by the fact that people actually get tired and sell out then. Things will probably improve somewhat in the weeks but no one can know exactly when. Good news can certainly do something. But how much does it help, and such?- ·2 päivää sitten · Muokattuhttps://forum.placera.se/inlagg/86cf80fb-16f7-4c37-a235-d0331e7ec7a3 Bada-bing-bada-bom Unknown if we get anything from Immunovia. But we have something called a Christmas rally that occurs almost 80 % of the years. Gemini AI describes: 🎄 The Christmas Stock Market Rally, often called the "Santa Claus Rally," refers to a historical tendency for the stock market to experience a short-term, sustained rise in price towards the very end of the year and the start of the new one. Here is a breakdown of what the rally is, its traditional timing, and the theories behind it: 🌟 What is the Santa Claus Rally? Definition: It is a well-known calendar effect in which the stock market, particularly in developed markets like the US (S&P 500), typically sees positive returns during a specific period around the Christmas and New Year holidays. Traditional Timing: The rally is most strictly defined as the period encompassing the last five trading days of December and the first two trading days of the following January (a total of seven trading days). Historical Performance: Since 1950, the S&P 500 index has historically posted a positive return during this seven-day window about 75-80% of the time, with an average gain of around 1.3%. Why Might the Rally Occur? (Key Theories) There is no single, universally accepted reason for this phenomenon, but several psychological and technical factors are commonly cited: Holiday Optimism and Sentiment: A general sense of goodwill, optimism, and increased consumer spending during the festive season might spill over into investor sentiment, encouraging more buying. Tax-Loss Harvesting Ends: In the early parts of December, some investors sell losing stocks to "harvest" losses to offset capital gains for tax purposes. This selling pressure eases up after the end of the year, allowing prices to rise. Lighter Trading Volume: Many institutional investors, like fund managers, take vacations around the holidays. This results in lower overall trading volume, meaning that smaller buy orders from individual (retail) investors can have a disproportionately larger effect on moving prices higher. Retail investors are often considered more bullish than institutions during this period. The "January Effect" Anticipation: Some investors may buy stocks in late December in anticipation of the January Effect, a separate historical tendency for stock prices, particularly small-cap stocks, to rise in January. Bonus Investment: Year-end bonuses are sometimes received and quickly invested by individuals, adding fresh capital to the market. While the Santa Claus Rally is a statistically observed pattern, it is not a guarantee: Not Every Year: The rally does not occur every year. The absence of a rally is sometimes viewed by analysts as a potentially negative indicator for the market's performance in the following year (as the saying goes: "If Santa Claus should fail to call, bears may come to Broad and Wall."). Past Performance: Like all market anomalies, the Santa Claus Rally is an observed historical tendency, and past performance is never a guarantee of future results. Long-term investment decisions should always be based on fundamental factors, not just seasonal patterns.
- ·2 päivää sitten · MuokattuVWAP at 0,3039 Tuesday 2. December must surely be considered a decent change in trend, despite marginal increases. Just the fact that it turned ever so slightly makes me a little happy. Long way until Christmas 🎅🦌
- ·3 päivää sittenThe management many years ago at Immunovia was incompetent. Among other things, they managed no less than twice to announce that everything was going according to plan regarding the launch of the precursor to PancreaSure, namely the Pancrea-d test. Only to tell a few weeks later, oops we can't stick to the plan after all. But apart from that, they were much better at communicating what their technology can actually do. Here is a quote from Immunovia.com anno 2020 via Wayback Machine: IMMray™ PanCan-d is our first product, but battling pancreatic cancer is only the beginning for us at Immunovia. We believe that our blood contains enough information to detect any disease, even at early stages. And we believe we have the technology to do it.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
8 päivää sittenUutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·9 t sittenThere isn't much news to be found at the moment. I asked Gemini AI a bit about these clinics and KOLs. Got this as an explanation for the news drought: 1. Targeted Advocacy Strategy (Focus on Quality over Quantity) Immunovia is currently in the "Targeted Advocacy" phase of their commercial launch. Initial Goal: The primary objective is not to maximize the number of centers, but to establish the test within the most influential, Key Opinion Leader (KOL)-led High-Risk Surveillance Centers (HRSCs). The Power of the First 10: Announcing the first set of 7 (and then the quick expansion to 10) was a key milestone to demonstrate proof of concept and KOL validation. Once that message is delivered, simply adding centers 11, 12, and 13 becomes less impactful public relations. Quiet Trust-Building: The commercial strategy is to work closely and quietly with these initial centers to build test volume and gather clinical utility data. These small, steady wins are vital for the business but not material enough for individual press releases. 2. Avoiding Unnecessary Revenue Expectations Announcing every new center can set an unrealistic expectation for revenue growth among investors. Since PancreaSure is currently a patient-pay test (until full Medicare/insurance reimbursement kicks in, which is planned for 2026), the initial test volume is expected to be modest. Each new center might only order a handful of tests initially as they integrate it into their protocol. Drip-feed announcements of small clinical wins could lead to investor fatigue or panic if the revenue numbers don't immediately follow the center count. Immunovia is likely waiting to announce a consolidated milestone (e.g., "We have secured 25 HRSCs," or "Quarterly test volume has doubled"). 3. Focus on Major Financial Milestones For a publicly traded company, press releases are generally reserved for material, market-moving events (those that could reasonably affect the share price). The company is prioritizing major milestones that unlock substantial future revenue: Final Medicare Payment Rate ($897): This was announced because it directly addresses the reimbursement bottleneck. Rights Issue/Financing: Announced to ensure liquidity. Major Validation Studies (CLARITI/VERIFI): Announced to provide scientific credibility. Adding center 11 is important for the sales team, but securing the Medicare price is what opens the door to the target 1.8 million high-risk U.S. individuals—a far more impactful announcement. In short, the lack of a press briefing for every new center is a sign of a focused, disciplined commercial strategy that prioritizes deep, high-quality adoption by key medical centers over a public relations race to count the most locations.·8 t sitten · MuokattuWe'll see if more centers emerge in December. Their goal was to collaborate with 15-20 by the end of 2025, and as it looks now, they don't seem to be able to meet that goal, unless they are very fast. I think it's very quiet. Their previous test, IMMray, was available at 23 centers.·7 t sittenDon't forget the Christmas rally before and after New Year
- ·14 t sitten · Muokattu* Pancreasure is the only reliable blood test for early pancreatic cancer. * Price $897, set by Medicare/Medicaid * Today it is offered for $750 at approximately 20 selected clinics and patients, if they are financially vulnerable, can get the price significantly reduced. * A blood test takes a few minutes to perform by a nurse. The best alternative, which has much higher accuracy, is EUS-FNB (endoscopic ultrasound-assisted fine-needle biopsy), i.e., one goes in with a needle probe through the esophagus into the stomach and perforates the bottom, inserts the needle into the pancreas which is located in the middle of the abdominal cavity under the stomach. All the time guided by ultrasound. It therefore requires a full medical team including an anesthesiologist. It takes a lot of time and several doctor's visits. It costs a total of $5000-$15000 when one includes * Pre-op imaging diagnostics * Pre-op lab Anesthesia * Facility fee * Pathology * Consultations With insurance, the patient pays $500-$4500 Here are some quotes: Dr. Diane Simeone, Director of Moores Cancer Center at UC San Diego and Founding Director of the PRECEDE Consortium, added that, “The PRECEDE Consortium is pleased to be collaborating with Immunovia as part of our common goal of finding a way to reliably detect pancreatic cancer at its earliest, most treatable stages.” Professor Bryson Katona, MD, Director, Gastrointestinal Cancer Genetics Program, University of Pennsylvania Perelman School of Medicine: ”The launch of the PancreaSure test is an important advance in pancreatic cancer surveillance. We have long recognized the need for blood-based tests to accurately detect early-stage pancreatic cancer in high-risk individuals and we are excited to offer this test in our program.” Bryson Katona also presented PancreaSure during the conference The Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC) on October 10 - in his capacity as former chairman and also a member of Immunovia's Scientific Advisory Board. Erkut Borazanci, MD, Medical Director, HonorHealth Research Institute, Oncology Research Division ”People at risk for pancreatic cancer often ask if there is a blood test to detect the disease. PancreaSure is a big step in that direction. It’s exciting to be able to offer high-risk individuals a convenient blood test that can be used in conjunction with imaging that may be able to detect pancreatic cancer.” Rosario Ligesti, MD, Chief of Gastroenterology, Hackensack Medical Center ”Pancreatic cancer is so lethal because it’s usually diagnosed too late. We need more ways to detect pancreatic cancer early, especially in people at high risk. The PancreaSure test has proven to accurately detect stage 1 and 2 disease, making it an important addition to our toolkit.”·13 t sitten · MuokattuThanks for trying to provide good data. I think we should be glad that Jeff Borcherdinger is not the type of CEO who churns out reports indiscriminately. I have observed other public limited companies that are a bit less serious. I think he has done as well as he can with the data he has had. We naturally had to go through the share issue. It turned out as it did with a stream of perfectly fine news that hit at not entirely optimal times. It was serious. Otherwise, one notices that the low volume is unfortunately being used by short traders again. Also, there is just as much downward manipulation for the share price as there is upward manipulative type. Down possibly wins because there are short opportunities. It is quite clear that the one with the deepest pockets is using the current opportunity to wear out owners into selling. That's their game when they can gradually build up a few more and more shares. Well aided by the fact that people actually get tired and sell out then. Things will probably improve somewhat in the weeks but no one can know exactly when. Good news can certainly do something. But how much does it help, and such?
- ·2 päivää sitten · Muokattuhttps://forum.placera.se/inlagg/86cf80fb-16f7-4c37-a235-d0331e7ec7a3 Bada-bing-bada-bom Unknown if we get anything from Immunovia. But we have something called a Christmas rally that occurs almost 80 % of the years. Gemini AI describes: 🎄 The Christmas Stock Market Rally, often called the "Santa Claus Rally," refers to a historical tendency for the stock market to experience a short-term, sustained rise in price towards the very end of the year and the start of the new one. Here is a breakdown of what the rally is, its traditional timing, and the theories behind it: 🌟 What is the Santa Claus Rally? Definition: It is a well-known calendar effect in which the stock market, particularly in developed markets like the US (S&P 500), typically sees positive returns during a specific period around the Christmas and New Year holidays. Traditional Timing: The rally is most strictly defined as the period encompassing the last five trading days of December and the first two trading days of the following January (a total of seven trading days). Historical Performance: Since 1950, the S&P 500 index has historically posted a positive return during this seven-day window about 75-80% of the time, with an average gain of around 1.3%. Why Might the Rally Occur? (Key Theories) There is no single, universally accepted reason for this phenomenon, but several psychological and technical factors are commonly cited: Holiday Optimism and Sentiment: A general sense of goodwill, optimism, and increased consumer spending during the festive season might spill over into investor sentiment, encouraging more buying. Tax-Loss Harvesting Ends: In the early parts of December, some investors sell losing stocks to "harvest" losses to offset capital gains for tax purposes. This selling pressure eases up after the end of the year, allowing prices to rise. Lighter Trading Volume: Many institutional investors, like fund managers, take vacations around the holidays. This results in lower overall trading volume, meaning that smaller buy orders from individual (retail) investors can have a disproportionately larger effect on moving prices higher. Retail investors are often considered more bullish than institutions during this period. The "January Effect" Anticipation: Some investors may buy stocks in late December in anticipation of the January Effect, a separate historical tendency for stock prices, particularly small-cap stocks, to rise in January. Bonus Investment: Year-end bonuses are sometimes received and quickly invested by individuals, adding fresh capital to the market. While the Santa Claus Rally is a statistically observed pattern, it is not a guarantee: Not Every Year: The rally does not occur every year. The absence of a rally is sometimes viewed by analysts as a potentially negative indicator for the market's performance in the following year (as the saying goes: "If Santa Claus should fail to call, bears may come to Broad and Wall."). Past Performance: Like all market anomalies, the Santa Claus Rally is an observed historical tendency, and past performance is never a guarantee of future results. Long-term investment decisions should always be based on fundamental factors, not just seasonal patterns.
- ·2 päivää sitten · MuokattuVWAP at 0,3039 Tuesday 2. December must surely be considered a decent change in trend, despite marginal increases. Just the fact that it turned ever so slightly makes me a little happy. Long way until Christmas 🎅🦌
- ·3 päivää sittenThe management many years ago at Immunovia was incompetent. Among other things, they managed no less than twice to announce that everything was going according to plan regarding the launch of the precursor to PancreaSure, namely the Pancrea-d test. Only to tell a few weeks later, oops we can't stick to the plan after all. But apart from that, they were much better at communicating what their technology can actually do. Here is a quote from Immunovia.com anno 2020 via Wayback Machine: IMMray™ PanCan-d is our first product, but battling pancreatic cancer is only the beginning for us at Immunovia. We believe that our blood contains enough information to detect any disease, even at early stages. And we believe we have the technology to do it.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
62
Myynti
Määrä
50 439
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 41 | - | - | ||
| 3 | - | - | ||
| 6 | - | - | ||
| 12 | - | - | ||
| 250 | - | - |
Ylin
0,3VWAP
Alin
0,283VaihtoMäärä
1 3 456 106
VWAP
Ylin
0,3Alin
0,283VaihtoMäärä
1 3 456 106
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 24.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 26.11. | |
| 2025 Q2 -tulosraportti | 28.8. | |
| 2025 Q1 -tulosraportti | 14.5. | |
| 2024 Q4 -tulosraportti | 25.2. | |
| 2024 Q3 -tulosraportti | 27.11.2024 |
Datan lähde: Quartr, FactSet
2025 Q3 -tulosraportti
8 päivää sittenUutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 24.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 26.11. | |
| 2025 Q2 -tulosraportti | 28.8. | |
| 2025 Q1 -tulosraportti | 14.5. | |
| 2024 Q4 -tulosraportti | 25.2. | |
| 2024 Q3 -tulosraportti | 27.11.2024 |
Datan lähde: Quartr, FactSet
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·9 t sittenThere isn't much news to be found at the moment. I asked Gemini AI a bit about these clinics and KOLs. Got this as an explanation for the news drought: 1. Targeted Advocacy Strategy (Focus on Quality over Quantity) Immunovia is currently in the "Targeted Advocacy" phase of their commercial launch. Initial Goal: The primary objective is not to maximize the number of centers, but to establish the test within the most influential, Key Opinion Leader (KOL)-led High-Risk Surveillance Centers (HRSCs). The Power of the First 10: Announcing the first set of 7 (and then the quick expansion to 10) was a key milestone to demonstrate proof of concept and KOL validation. Once that message is delivered, simply adding centers 11, 12, and 13 becomes less impactful public relations. Quiet Trust-Building: The commercial strategy is to work closely and quietly with these initial centers to build test volume and gather clinical utility data. These small, steady wins are vital for the business but not material enough for individual press releases. 2. Avoiding Unnecessary Revenue Expectations Announcing every new center can set an unrealistic expectation for revenue growth among investors. Since PancreaSure is currently a patient-pay test (until full Medicare/insurance reimbursement kicks in, which is planned for 2026), the initial test volume is expected to be modest. Each new center might only order a handful of tests initially as they integrate it into their protocol. Drip-feed announcements of small clinical wins could lead to investor fatigue or panic if the revenue numbers don't immediately follow the center count. Immunovia is likely waiting to announce a consolidated milestone (e.g., "We have secured 25 HRSCs," or "Quarterly test volume has doubled"). 3. Focus on Major Financial Milestones For a publicly traded company, press releases are generally reserved for material, market-moving events (those that could reasonably affect the share price). The company is prioritizing major milestones that unlock substantial future revenue: Final Medicare Payment Rate ($897): This was announced because it directly addresses the reimbursement bottleneck. Rights Issue/Financing: Announced to ensure liquidity. Major Validation Studies (CLARITI/VERIFI): Announced to provide scientific credibility. Adding center 11 is important for the sales team, but securing the Medicare price is what opens the door to the target 1.8 million high-risk U.S. individuals—a far more impactful announcement. In short, the lack of a press briefing for every new center is a sign of a focused, disciplined commercial strategy that prioritizes deep, high-quality adoption by key medical centers over a public relations race to count the most locations.·8 t sitten · MuokattuWe'll see if more centers emerge in December. Their goal was to collaborate with 15-20 by the end of 2025, and as it looks now, they don't seem to be able to meet that goal, unless they are very fast. I think it's very quiet. Their previous test, IMMray, was available at 23 centers.·7 t sittenDon't forget the Christmas rally before and after New Year
- ·14 t sitten · Muokattu* Pancreasure is the only reliable blood test for early pancreatic cancer. * Price $897, set by Medicare/Medicaid * Today it is offered for $750 at approximately 20 selected clinics and patients, if they are financially vulnerable, can get the price significantly reduced. * A blood test takes a few minutes to perform by a nurse. The best alternative, which has much higher accuracy, is EUS-FNB (endoscopic ultrasound-assisted fine-needle biopsy), i.e., one goes in with a needle probe through the esophagus into the stomach and perforates the bottom, inserts the needle into the pancreas which is located in the middle of the abdominal cavity under the stomach. All the time guided by ultrasound. It therefore requires a full medical team including an anesthesiologist. It takes a lot of time and several doctor's visits. It costs a total of $5000-$15000 when one includes * Pre-op imaging diagnostics * Pre-op lab Anesthesia * Facility fee * Pathology * Consultations With insurance, the patient pays $500-$4500 Here are some quotes: Dr. Diane Simeone, Director of Moores Cancer Center at UC San Diego and Founding Director of the PRECEDE Consortium, added that, “The PRECEDE Consortium is pleased to be collaborating with Immunovia as part of our common goal of finding a way to reliably detect pancreatic cancer at its earliest, most treatable stages.” Professor Bryson Katona, MD, Director, Gastrointestinal Cancer Genetics Program, University of Pennsylvania Perelman School of Medicine: ”The launch of the PancreaSure test is an important advance in pancreatic cancer surveillance. We have long recognized the need for blood-based tests to accurately detect early-stage pancreatic cancer in high-risk individuals and we are excited to offer this test in our program.” Bryson Katona also presented PancreaSure during the conference The Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC) on October 10 - in his capacity as former chairman and also a member of Immunovia's Scientific Advisory Board. Erkut Borazanci, MD, Medical Director, HonorHealth Research Institute, Oncology Research Division ”People at risk for pancreatic cancer often ask if there is a blood test to detect the disease. PancreaSure is a big step in that direction. It’s exciting to be able to offer high-risk individuals a convenient blood test that can be used in conjunction with imaging that may be able to detect pancreatic cancer.” Rosario Ligesti, MD, Chief of Gastroenterology, Hackensack Medical Center ”Pancreatic cancer is so lethal because it’s usually diagnosed too late. We need more ways to detect pancreatic cancer early, especially in people at high risk. The PancreaSure test has proven to accurately detect stage 1 and 2 disease, making it an important addition to our toolkit.”·13 t sitten · MuokattuThanks for trying to provide good data. I think we should be glad that Jeff Borcherdinger is not the type of CEO who churns out reports indiscriminately. I have observed other public limited companies that are a bit less serious. I think he has done as well as he can with the data he has had. We naturally had to go through the share issue. It turned out as it did with a stream of perfectly fine news that hit at not entirely optimal times. It was serious. Otherwise, one notices that the low volume is unfortunately being used by short traders again. Also, there is just as much downward manipulation for the share price as there is upward manipulative type. Down possibly wins because there are short opportunities. It is quite clear that the one with the deepest pockets is using the current opportunity to wear out owners into selling. That's their game when they can gradually build up a few more and more shares. Well aided by the fact that people actually get tired and sell out then. Things will probably improve somewhat in the weeks but no one can know exactly when. Good news can certainly do something. But how much does it help, and such?
- ·2 päivää sitten · Muokattuhttps://forum.placera.se/inlagg/86cf80fb-16f7-4c37-a235-d0331e7ec7a3 Bada-bing-bada-bom Unknown if we get anything from Immunovia. But we have something called a Christmas rally that occurs almost 80 % of the years. Gemini AI describes: 🎄 The Christmas Stock Market Rally, often called the "Santa Claus Rally," refers to a historical tendency for the stock market to experience a short-term, sustained rise in price towards the very end of the year and the start of the new one. Here is a breakdown of what the rally is, its traditional timing, and the theories behind it: 🌟 What is the Santa Claus Rally? Definition: It is a well-known calendar effect in which the stock market, particularly in developed markets like the US (S&P 500), typically sees positive returns during a specific period around the Christmas and New Year holidays. Traditional Timing: The rally is most strictly defined as the period encompassing the last five trading days of December and the first two trading days of the following January (a total of seven trading days). Historical Performance: Since 1950, the S&P 500 index has historically posted a positive return during this seven-day window about 75-80% of the time, with an average gain of around 1.3%. Why Might the Rally Occur? (Key Theories) There is no single, universally accepted reason for this phenomenon, but several psychological and technical factors are commonly cited: Holiday Optimism and Sentiment: A general sense of goodwill, optimism, and increased consumer spending during the festive season might spill over into investor sentiment, encouraging more buying. Tax-Loss Harvesting Ends: In the early parts of December, some investors sell losing stocks to "harvest" losses to offset capital gains for tax purposes. This selling pressure eases up after the end of the year, allowing prices to rise. Lighter Trading Volume: Many institutional investors, like fund managers, take vacations around the holidays. This results in lower overall trading volume, meaning that smaller buy orders from individual (retail) investors can have a disproportionately larger effect on moving prices higher. Retail investors are often considered more bullish than institutions during this period. The "January Effect" Anticipation: Some investors may buy stocks in late December in anticipation of the January Effect, a separate historical tendency for stock prices, particularly small-cap stocks, to rise in January. Bonus Investment: Year-end bonuses are sometimes received and quickly invested by individuals, adding fresh capital to the market. While the Santa Claus Rally is a statistically observed pattern, it is not a guarantee: Not Every Year: The rally does not occur every year. The absence of a rally is sometimes viewed by analysts as a potentially negative indicator for the market's performance in the following year (as the saying goes: "If Santa Claus should fail to call, bears may come to Broad and Wall."). Past Performance: Like all market anomalies, the Santa Claus Rally is an observed historical tendency, and past performance is never a guarantee of future results. Long-term investment decisions should always be based on fundamental factors, not just seasonal patterns.
- ·2 päivää sitten · MuokattuVWAP at 0,3039 Tuesday 2. December must surely be considered a decent change in trend, despite marginal increases. Just the fact that it turned ever so slightly makes me a little happy. Long way until Christmas 🎅🦌
- ·3 päivää sittenThe management many years ago at Immunovia was incompetent. Among other things, they managed no less than twice to announce that everything was going according to plan regarding the launch of the precursor to PancreaSure, namely the Pancrea-d test. Only to tell a few weeks later, oops we can't stick to the plan after all. But apart from that, they were much better at communicating what their technology can actually do. Here is a quote from Immunovia.com anno 2020 via Wayback Machine: IMMray™ PanCan-d is our first product, but battling pancreatic cancer is only the beginning for us at Immunovia. We believe that our blood contains enough information to detect any disease, even at early stages. And we believe we have the technology to do it.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
62
Myynti
Määrä
50 439
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 41 | - | - | ||
| 3 | - | - | ||
| 6 | - | - | ||
| 12 | - | - | ||
| 250 | - | - |
Ylin
0,3VWAP
Alin
0,283VaihtoMäärä
1 3 456 106
VWAP
Ylin
0,3Alin
0,283VaihtoMäärä
1 3 456 106
Välittäjätilasto
Dataa ei löytynyt